Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI (Mirdametinib), Manufactured By SpringWorks Therapeutics

GlobeNewswire16:05 ET

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

BenzingaFeb 16 09:45 ET

Key Deals This Week: Papa John's, Spirit Airlines, Novartis, Banco Santander and More

Seeking AlphaFeb 15 15:15 ET

Earnings Preview: SWTX to Report Financial Results Pre-market on February 20

Moomoo NewsFeb 14 20:00 ET

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaFeb 14 12:35 ET

SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Feb 13 09:10 ET

BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $87

Moomoo NewsFeb 13 07:33 ET · Ratings

SpringWorks Therapeutics Insider Sold Shares Worth $1,617,329, According to a Recent SEC Filing

MT NewswiresFeb 13 04:11 ET

Evercore Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $65

Moomoo NewsFeb 13 01:31 ET · Ratings

SpringWorks Therapeutics(SWTX.US) Director Sells US$9.53 Million in Common Stock

Moomoo NewsFeb 12 20:02 ET

SpringWorks Therapeutics Sets Wholesale Acquisition Cost for GOMEKLI at $206.25

TipRanksFeb 12 10:50 ET

Wedbush Adjusts Price Target on Springworks Therapeutics to $81 From $77, Maintains Outperform Rating

MT NewswiresFeb 12 10:23 ET · Ratings

TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $66

Moomoo NewsFeb 12 09:31 ET · Ratings

SpringWorks Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow JonesFeb 12 09:30 ET · Ratings

SpringWorks Therapeutics Price Target Raised to $65.00/Share From $60.00 by Evercore ISI Group

Dow JonesFeb 12 09:30 ET · Ratings

SpringWorks Therapeutics Price Target Raised to $66 From $63 at TD Cowen

TipRanksFeb 12 08:35 ET

SpringWorks Therapeutics Analyst Ratings

BenzingaFeb 12 07:41 ET · Ratings

H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $74

Moomoo NewsFeb 12 06:31 ET · Ratings

Buy Rating for Springworks Therapeutics Boosted by FDA Approval of GOMEKLI and Strong Market Potential

TipRanksFeb 12 06:18 ET · Ratings

SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder

MT NewswiresFeb 12 04:56 ET